Sihe Zhang | Pharmacology | Best Researcher Award

Published on by Global Academic Awards

Prof Sihe Zhang | Pharmacology | Best Researcher Award

Professor at  Nankai University, China

Si-he Zhang is a distinguished cell biologist and professor at Nankai University, China. He earned his PhD in Cell Biology from the Fourth Military Medical University and has held various academic positions including Associate Professor at Lund University Hospital, Sweden. His research focuses on cancer biology, particularly in developing targeted therapies using antibodies and nanoparticle-based drug delivery systems. Zhang has authored numerous influential publications and holds several key patents in the field. He has received prestigious awards, including the Chinese Outstanding Patented Invention Gold Award and the National Prize for Progress in Science & Technology. Zhang also serves on several scholarly committees and as a consultant for leading biopharmaceutical companies in China.

Profile

Scopus

Education:

  • PhD in Cell Biology, Fourth Military Medical University, China, 2001-2004
  • M.A. in Genetics, Jinlin University, China, 1996-1998
  • B.S. in Genetics, Northwest A&F University, China, 1991-1995

Positions Held:

  • Tenured Full Professor, Nankai University, China (2020-present)
  • Tenured Associate Professor, Nankai University, China (2012-2019)
  • Postdoctoral Scientist, Lund University Hospital, Sweden (2006-2009)
  • Associate Professor, Fourth Military Medical University, China (2005-2011)
  • Lecturer, Fourth Military Medical University, China (2000-2005)
  • Teaching Assistant, Fourth Military Medical University, China (1998-2000)

Major Awards:

  • Gold Award for Chinese Outstanding Patented Invention, WIPO-SIPO (2010)
  • National Prize for Progress in Science & Technology, China (2005)

Citations:

  • Citations: 948
  • Documents Contributed: 43
  • h-index: 15

Publications Top Notes

  • Hypoxia-activated ADCC-enhanced humanized anti-CD147 antibody for liver cancer imaging and targeted therapy with improved selectivity
    • Qi, F.-Z., Su, H.-S., Wang, B., …, Chen, Z.-N., Zhang, S.-H.
    • MedComm, 2024, 5(3), e512
  • Suicide gene delivery by morphology-adaptable enantiomeric peptide assemblies for combined ovarian cancer therapy
    • Song, N., Sun, Z., Wang, B., …, Zhang, S., Yu, Z.
    • Acta Biomaterialia, 2024, 175, pp. 250–261
  • Vesicle-mediated transport-related genes predict the prognosis and immune microenvironment in hepatocellular carcinoma
    • Ye, Z., Wang, Y., Yuan, R., …, Qian, L., Zhang, S.
    • Journal of Cancer, 2024, 15(12), pp. 3645–3662
  • Hypoxia-activated selectivity-improved anti-PKM2 antibody combined with prodrug TH-302 for potentiated targeting therapy in hepatocellular carcinoma
    • Wang, B., Qi, F.-Z., Chen, P., …, Chen, Z.-S., Zhang, S.-H.
    • International Journal of Biological Sciences, 2024, 20(5), pp. 1634–1651
  • Cell-Penetrating Peptide-Based Delivery of Macromolecular Drugs: Development, Strategies, and Progress
    • Sun, Z., Huang, J., Fishelson, Z., Wang, C., Zhang, S.
    • Biomedicines, 2023, 11(7), 1971
  • GRP75-driven, cell-cycle-dependent macropinocytosis of Tat/pDNA-Ca2+ nanoparticles underlies distinct gene therapy effect in ovarian cancer
    • Su, L., Sun, Z., Qi, F., …, Chen, Z., Zhang, S.
    • Journal of Nanobiotechnology, 2022, 20(1), 340
  • Novel GIRlncRNA Signature for Predicting the Clinical Outcome and Therapeutic Response in NSCLC
    • Zhang, Q., Liu, X., Chen, Z., Zhang, S.
    • Frontiers in Pharmacology, 2022, 13, 937531

 

Vahideh Mohammadzadeh | Pharmacology Award | Best Researcher Award

Published on by Global Academic Awards

Dr. Vahideh Mohammadzadeh | Pharmacology Award | Best Researcher Award

Dr. Vahideh Mohammadzadeh, mashhad university of medical science, Iran

Dr. Vahideh Mohammadzadeh is a Ph.D. student in Pharmaceutical Nanotechnology at Mashhad University of Medical Sciences, Iran. Her research focuses on innovative drug delivery systems like nanoliposomes for treating cancer and eye diseases. With expertise in nanoformulations (liposome, micelle, polymer), she conducts in-vitro assays and specializes in MTT assay and HPLC. Her work spans biochemistry, immunology, and nanomedicine, highlighted by numerous publications on nanosensors, therapeutic nanoparticles, and drug delivery advancements. Dr. Mohammadzadeh is also skilled in statistical analysis, technical writing, and communication. She aims to revolutionize healthcare through cutting-edge pharmaceutical nanotechnology. 📚💊

 

Publication Profile

Professional Background

Dr. Vahideh Mohammadzadeh is currently pursuing her Ph.D. in Pharmaceutical Nanotechnology at Mashhad University of Medical Sciences, Iran. Her research primarily focuses on advancing drug delivery systems, particularly through nanotechnology. She specializes in the formulation of nanoliposomes and other nanostructures like micelles and polymers for targeted therapy in cancer and ocular diseases. Dr. Mohammadzadeh has extensive experience in conducting in-vitro biochemical and immunological assays, including MTT assay and HPLC analysis. Her work is underscored by a prolific publication record encompassing topics such as nanosensors, therapeutic nanoparticles, and innovative drug formulations. 📊🔬

Education

Ph.D., Pharmaceutical Nanotechnology, Mashhad University of Medical Sciences, 2018-2024

M.Sc., Toxicology, Mashhad University of Medical Sciences, 2014-2017

B.Sc., Biology

Research Focus

Dr. Vahideh Mohammadzadeh’s research primarily focuses on advancing drug delivery systems in cancer therapy through innovative nanotechnologies. Her work spans the development and characterization of nanoliposomes, polymeric micelles, and other nanostructures to enhance the targeted delivery of therapeutic agents for cancer and ocular diseases. She explores novel formulations like liposomes and plant-based nanoparticles to optimize drug efficacy while minimizing side effects. Dr. Mohammadzadeh’s research also delves into nanosensors for biomolecule detection and the biological synthesis of nanoparticles for cytotoxicity studies. Her contributions aim to revolutionize healthcare through cutting-edge nanomedicine solutions. 🌟🔬

 

Publication Top Notes

  • Poly-γ-glutamic acid nanoparticles as adjuvant and antigen carrier system for cancer vaccination 📄 Citations: 14 | Cited by: Jaafari, M.R. et al. | Year: 2023
  • Plant Gel-Mediated Synthesis of Gold-Coated Nanoceria Using Ferula gummosa: Characterization and Estimation of Its Cellular Toxicity toward Breast Cancer Cell Lines 📄 Citations: 14 | Cited by: Sarafraz Ardakani, M.R. et al. | Year: 2023
  • Icariin: A Promising Natural Product in Biomedicine and Tissue Engineering 📄 Citations: 22 | Cited by: Simal-Gandara, J. et al. | Year: 2023
  • Correction to: New insights into the application of nanoghosts as theranostic tools with an emphasis on cardiovascular diseases 📄 Citations: 1 | Cited by: Qindeel, M. et al. | Year: 2022
  • Novel EPR-enhanced strategies for targeted drug delivery in pancreatic cancer: An update 📄 Citations: 21 | Cited by: Sibuh, B.Z. et al. | Year: 2022
  • Fluorescent-based nanosensors for selective detection of a wide range of biological macromolecules: A comprehensive review 📄 Citations: 106 | Cited by: Díez-Pascual, A.M. et al. | Year: 2022
  • Applications of plant-based nanoparticles in nanomedicine: A review 📄 Citations: 84 | Cited by: Varma, R.S. et al. | Year: 2022
  • Biological synthesis and characterization of gold nanoparticles using Verbascum speciosum Schrad. and cytotoxicity properties toward HepG2 cancer cell line 📄 Citations: 35 | Cited by: Nadaf, M. et al. | Year: 2022
  • Theranostic advances of bionanomaterials against gestational diabetes mellitus: A preliminary review 📄 Citations: 24 | Cited by: Thakur, V.K. et al. | Year: 2021